Company expects multiple clinical and regulatory milestones in coming quarters across core programs
Medicus anticipates potential expansion of strategic collaborations and licensing discussions
Company says substantial doubt exists about ability to continue as a going concern without more financing
Overview
US biotech firm's Q2 net loss widened and operating expenses increased yr/yr
Company raised ~$40 mln in equity and debt, boosting liquidity but faces going concern risk
Company achieved key FDA and international study authorizations for SkinJect and Teverelix programs
Result Drivers
R&D SPENDING - Research and development expenses rose to $4.9 mln from $1.4 mln in Q2 2025 as co advanced clinical programs
REGULATORY MILESTONES - Co cited FDA and international study authorizations for SkinJect and Teverelix as key achievements supporting pipeline progress
HIGHER OPERATING COSTS - Operating expenses increased to $11.5 mln from $6.0 mln in Q2 2025, reflecting expanded clinical and corporate activities
MDCX•
